Previous 10 | Next 10 |
2024-05-16 06:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-15 11:45:04 ET More on Arcutis Biotherapeutics Arcutis Biotherapeutics, Inc. (ARQT) Q1 2024 Earnings Call Transcript Arcutis Biotherapeutics: Betting Big On Zoryve Arcutis Biotherapeutics, Inc. (ARQT) Q4 2023 Earnings Call Transcript Arcutis announces...
2024-05-14 19:47:10 ET Arcutis Biotherapeutics, Inc. (ARQT) Q1 2024 Earnings Conference Call May 14, 2024, 4:30 PM ET Company Participants Latha Vairavan - Vice President, Finance and Head of Investor Relations Frank Watanabe - President and Chief Executive Officer ...
2024-05-14 16:22:07 ET More on Arcutis Biotherapeutics Arcutis Biotherapeutics: Betting Big On Zoryve Arcutis Biotherapeutics, Inc. (ARQT) Q4 2023 Earnings Call Transcript Arcutis announces pricing of $150 million public offering Arcutis licenses Japanese rig...
First quarter net product revenues for ZORYVE® franchise of $21.6M, with $15M for ZORYVE (roflumilast) cream 0.3%, and $6.5M for ZORYVE (roflumilast) topical foam, 0.3%; sales growth of 675% vs. Q1 '23 and 59% vs. Q4 '23 Continued gross-to-net (GTN) improvement with blended GTN across pr...
2024-05-13 17:35:40 ET More on Arcutis Biotherapeutics Arcutis Biotherapeutics: Betting Big On Zoryve Arcutis Biotherapeutics, Inc. (ARQT) Q4 2023 Earnings Call Transcript Arcutis announces pricing of $150 million public offering Arcutis licenses Japanese rig...
2024-05-13 17:35:36 ET Major earnings expected after the bell on Tuesday include: Oxford Lane Capital Corp. ( OXLC ) Capital Southwest Corporation ( CSWC ) Seadrill Limited ( SDRL ) Nu Holdings Ltd. ( NU ) Canoo ( GOEV ) Read the full articl...
Eight of nine experts expressed feeling “extremely confident” about prescribing ZORYVE foam to patients of diverse skin and hair types, including individuals with previous hair treatments, based on review of formulation data Crodafos™ CES, used in ZORYVE foam, is suitab...
2024-05-07 10:47:03 ET ProShares UltraPro Short QQQ (SQQQ) SQQQ is trading DOWN for the last 4 days, and it at trading at $10.69 with volume of 30,905,666 and a one day change of $-0.01 (-0.09%). ProShares UltraPro Short QQQ has a 52-week low of 10.05 and a 52-week high of $29.28. T...
2024-05-01 06:57:02 ET Summary Arcutis Biotherapeutics is a biopharmaceutical company focused on developing therapies for dermatological diseases. The company has received FDA approval for its drug Zoryve and is expecting further label expansions and approvals. While the compa...
News, Short Squeeze, Breakout and More Instantly...
Arcutis Biotherapeutics Inc. Company Name:
ARQT Stock Symbol:
NASDAQ Market:
Arcutis Biotherapeutics Inc. Website:
2024-06-16 18:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Investigational roflumilast cream 0.15% showed continued improvements in the signs and symptoms of AD, including itch, through 56 weeks of treatment 66.2% of participants treated with once-daily roflumilast cream 0.15% in both the 4-week parent study and the 52-week open label extension ach...